BioXcel Therapeutics (BTAI) Operating Expenses (2017 - 2026)

BioXcel Therapeutics has reported Operating Expenses for 10 years, with the latest figure at $10.4 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 35.04% year-over-year to $10.4 million in Q2 2026; TTM through Jun 2026 was $45.7 million, a 13.19% decrease from a year earlier, with the FY2025 full-year figure at $51.1 million, down 26.48% from the prior year.
• Operating Expenses was $10.4 million for Q2 2026 at BioXcel Therapeutics, down from $10.4 million in the prior quarter.
• The five-year high for Operating Expenses was $53.1 million in Q4 2022, with the low at $10.3 million in Q1 2025.
• Average Operating Expenses over 5 years is $26.4 million, with a median of $19.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses soared 103.33% in 2022, then sank 68.12% in 2024.
• Over 5 years, Operating Expenses stood at $53.1 million in 2022, then tumbled by 61.89% to $20.3 million in 2023, then plunged by 46.38% to $10.9 million in 2024, then fell by 2.96% to $10.5 million in 2025, then retreated by 1.55% to $10.4 million in 2026.
• The last three Operating Expenses figures came in at $10.4 million (Q2 2026), $10.4 million (Q1 2026), and $10.5 million (Q4 2025), per Business Quant data.